Cyclodextrin Diethyldithiocarbamate Copper II Inclusion Complexes: A Promising Chemotherapeutic Delivery System against Chemoresistant Triple Negative Breast Cancer Cell Lines

Diethyldithiocarbamate Copper II (DDC-Cu) has shown potent anticancer activity against a wide range of cancer cells, but further investigations are hindered by its practical insolubility in water. In this study, inclusion complexes DDC-Cu with hydroxypropyl beta-cyclodextrin (HP) or sulfobutyl ether (SBE) were prepared and investigated as an approach to enhance the apparent solubility DDC-Cu. Formulations simple mixing both cyclodextrin (CDs) at room temperature. Phase assessments resulting solutions performed. CD freeze-dried for characterisations DSC, thermogravimetric analysis (TGA) FT-IR. Stability cytotoxicity studies also performed investigate maintenance activity. The phase profile deviated positively from linearity (Ap type) showing significant enhancement (approximately 4 mg/mL 20% w/w solutions). DSC TGA confirmed solid solution status CD. stable 28 days conveyed on chemoresistant triple negative breast cell lines, IC50 values less than 200 nM. Overall, offer great potential applications, evidenced their very positive effects cells.